PPAR activators as antiinflammatory mediators in human T lymphocytes: Implications for atherosclerosis and transplantation-associated arteriosclerosis

Circulation Research

Volumn 90, Issue 6, 2002, Pages 703-710

  Marx, Nikolaus ^a   Kehrle, Bettina ^a   Kohlhammer, Klaus ^a   Grüb, Miriam ^a   Koenig, Wolfgang ^a   Hombach, Vinzenz ^a   Libby, Peter ^b   Plutzky, Jorge ^b  

^a UNIVERSITY OF ULM   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Fibrates; Peroxisome proliferator activated receptors; T cells; Thiazolidinediones

Indexed keywords

CD64 ANTIGEN; CYTOKINE; FENOFIBRATE; GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MONOCLONAL ANTIBODY CD3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PIRINIXIC ACID; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTERIOSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; CELL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; T LYMPHOCYTE;

ANTI-INFLAMMATORY AGENTS; ARTERIOSCLEROSIS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; PEROXISOME PROLIFERATORS; PROCETOFEN; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037023635     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000014225.20727.8F     Document Type: Article

References (45)

1. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques
2. + T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice
3. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque
4. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines
5. Interferon γ inhibits both proliferation and expression of differentiation-specific α-smooth muscle actin in arterial smooth muscle cells
6. Molecular bases of the acute coronary syndromes
7. Acute T-cell activation is detectable in unstable angina
8. Perturbation of the T-cell repertoire in patients with unstable angina
9. IFN-γ potentiates atherosclerosis in apoE knock-out mice
10. Human coronary transplantation-associated arteriosclerosis: Evidence for a chronic immune reaction to activated graft endothelial cells
11. Interferon-γ deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts
12. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
13. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
14. Macrophages in human atheroma contain PPARγ: Differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro
15. Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells
16. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule 1 expression in human endothelial cells
17. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
18. Peroxisome proliferator-activated receptors, orphans with ligands and functions
19. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
20. An antidiabetic thiazolidinedione is a high affinity ligand for PPAR γ
21. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
22. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
23. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: Possible mediators of cardiovascular risk?
24. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
25. Troglitazone inhibits atherosclerosis in apolipoprotein E-knock-out mice: Pleiotropic effects on CD36 expression and HDL
26. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
27. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
28. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb
29. Activation of human T lymphocytes is inhibited by PPARγ agonists: PPARγ co-association with transcription factor NFAT
30. The nuclear receptor PPAR γ and immunoregulation: PPAR γ mediates inhibition of helper T cell responses
31. PPARα activators inhibit tissue factor expression and activity in human monocytes
32. PPAR γ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease
33. Two essential regulatory elements in the human interferon γ promoter confer activation specific expression in T cells
34. Factors affecting the cytokine production of human T cells stimulated by different modes of activation
35. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets
36. Molecular fingerprints of interferon-γ signaling in unstable angina
37. The metabolism and disposition of 14C-fenofibrate in human volunteers
38. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
39. Activation of human PPAR subtypes by pioglitazone
40. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor and mediated by inhibition of translation initiation
41. PPAR-γ activation in naive mouse T cells induces cell death
42. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice
43. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
44. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus
45. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study